Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-04. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
In response to the attacks, Hezbollah made its deepest incursion into Israeli territory at the time by launching drone attacks into the city of Acre targeting two IDF bases. On 5 May, an Israel airstrike on a house in the Lebanese village of Meiss Ej Jabal killed four civilians. In retaliation, Hezbollah fired dozens of rockets at the Israeli town of Kiryat Shmona. On 6 May, two reservist Israeli soldiers of the 98th Paratroopers Division's 655th Battalion were killed by a Hezbollah drone attack near Metula, northern Israel, bringing the IDF death toll to 18. Hezbollah also launched 30 rockets at the Golan Heights, damaging houses in Kidmat Tzvi. The IDF struck 15 Radwan targets in al-Lwaiza, southern Lebanon, and a Hezbollah compound in Sefri, near Baalbek. Lebanese media said that the strike destroyed a factory and injured three people. On 8 May, Israeli airstrikes in southern Lebanon killed two Hezbollah and three PIJ members. The next day an Israeli airstrike on a car near the village of Bafliyeh killed four Hezbollah members. On 10 May, Israeli airstrikes on two villages in the Marjeyoun District killed a Hezbollah member in Aedsheet and a PIJ member in Blida, respectively. On the same day, another Israeli airstrike on the town of Tayr Harfa killed two civilians who were carrying out repairs on a local cell tower. On 14 May, an Israeli airstrike on a house in the village of Meiss Ej Jabal killed a member of Hezbollah and injured one other person.
Radioactive waste comes from a number of sources. In countries with nuclear power plants, nuclear armament, or nuclear fuel treatment plants, the majority of waste originates from the nuclear fuel cycle and nuclear weapons reprocessing. Other sources include medical and industrial wastes, as well as naturally occurring radioactive materials (NORM) that can be concentrated as a result of the processing or consumption of coal, oil, and gas, and some minerals, as discussed below.
== History == Two research teams independently identified mouse colony stimulating factors in the 1960s: Ray Bradley at University of Melbourne and Donald Metcalf at Walter and Eliza Hall Institute, from Australia, and Yasuo Ichikawa, Dov Pluznik and Leo Sachs at the Weizmann Institute of Science, Israel. In 1980 Antony Burgess and Donald Metcalf discovered that mouse lung conditioned medium contained at least two different CSFs - GM-CSF, which they had purified in 1977 and a G-CSF which stimulated the production of colonies of neutrophils. In 1983, Donald Metcalf's research team, led by Nicos Nicola, isolated the murine cytokine from medium conditioned with lung tissue obtained from endotoxin-treated mice. In 1985, Karl Welte, Erich Platzer, Janice Gabrilove, Roland Mertelsmann and Malcolm Moore at the Memorial Sloan Kettering Cancer Center (MSK) purified human G-CSF produced by bladder cancer cell line 5637 from conditioned medium. In 1986, Karl Welte's team at MSK patented the method of producing and using human G-CSF under the name "human hematopoietic pluripotent colony stimulating factor" or "human pluripotent colony stimulating factor" (P-CSF). Also in 1986, two independent research groups working with pharmaceutical companies cloned the G-CSF gene that made possible large-scale production and its clinical use: Shigekazu Nagata's team in collaboration with Chugai Pharmaceutical Co. from Japan, and Lawrence Souza's team at Amgen in collaboration with Karl Welte's research team members from Germany and the USA.
Use of higher doses of radioiodine reduces the number of cases of treatment failure, with a penalty for higher response to treatment consisting mostly of higher rates of eventual hypothyroidism, which requires hormone treatment for life. There is increased sensitivity to radioiodine therapy in thyroids appearing on ultrasound scans as more uniform (hypoechogenic), due to densely packed large cells, with 81% later becoming hypothyroid, compared to just 37% in those with more normal scan appearances (normoechogenic).
Sources: en.wikipedia.org
=== Interactions === Upwards of 12 interacting proteins have been predicted for C3orf62. Interacting proteins with the strongest confidence to interact with C3orf62 include: HAUS augmin-like complex subunit 1 (HAUS-1), Inhibitor of growth protein 5 (ING5), Thioredoxin domain-containing protein 9 (TXNDC9), and MORF4-family associated proteins (MORF4L1, MFRAP1). Chemicals known to interact with C3orf62 include the following: Aflatoxin B1, Hydralazine, Valproic acid, and Decitabine.
As an expression of gratitude for New Zealand's hospitality, he and others arranged a free event, We Love Aotearoa, with live performances from musicians across New Zealand. It was accompanied by VR stands for Valve games such as Half-Life: Alyx and The Lab. The event was postponed from August to December due to a lockdown induced by a second wave of COVID-19. Newell applied for permanent residency in New Zealand in October 2020, but had returned to Seattle by 2021. Since the 1990s, Newell has owned and sold several homes in Seattle, including a home in Capitol Hill, two homes on Lake Washington and a holiday home in Long Beach Peninsula. He owns several ships and has lived mostly at sea since the pandemic. In June 2026, he purchased a 20,000-square-foot mansion in Florida for $70.8 million, with 7 bedrooms, 13 bathrooms, an 8-car garage, an outdoor pool, a dock, a boat lift, an elevator, and a private tunnel to a beach. As of 2026, Newell had lost a substantial amount of weight.
Acute lymphoblastic leukemia (ALL) cells are CD10+. Follicular lymphoma (follicle centre cell lymphoma) are CD10+. Burkitt Lymphoma cells are CD10+. CD10+ diffuse large B cell lymphoma (CD10+ DLBCL) Marker for germinal center phenotype (CD10, HGAL, BCL6, CD38) are considered a favorable prognostic factor, but CD10+, BCL2+ tumors could have poorer survival. For some authors, CD10 expression in DLBCL does not influence survival. Angioimmunoblastic T cell lymphoma (AITL) are CD10+ and distinguishes AITL from other T cell lymphomas (CD10−) Some benign T cells can be CD10+
Lead was used for making water pipes in the Roman Empire; the Latin word for the metal, plumbum, is the origin of the English word "plumbing". Its ease of working, its low melting point enabling the easy fabrication of completely waterproof welded joints, and its resistance to corrosion ensured its widespread use in other applications, including pharmaceuticals, roofing, currency, warfare. Writers of the time, such as Cato the Elder, Columella, and Pliny the Elder, recommended lead (and lead-coated) vessels for the preparation of sweeteners and preservatives added to wine and food. The lead conferred an agreeable taste due to the formation of "sugar of lead" (lead(II) acetate), whereas copper vessels imparted a bitter flavor through verdigris formation.
== Research == Ala-Kokko's research focuses on collagen in cartilage, and connective tissue disorders. She has, with her research group, succeeded in identifying the errors in cartilage collagen that lead to the development of osteoarthritis and diseases of the vertebrae, amongst others. Her results have assisted in the diagnosis and care of patients, as well as improvements to the way in which these diseases are treated. She has published about 160 articles based on her research, and she has been awarded five patents.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.